The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global tuberculosis diagnostics market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Tuberculosis (TB) refers to an infectious bacterial disease that primarily affects the lungs (pulmonary), along with other parts of the body (extrapulmonary). The infection is diagnosed via a Mantoux tuberculin skin test (TST) or the TB blood test. Additional tests are required to confirm TB disease, depending on the infected organs. In the case of pulmonary TB, chest radiography is performed for detecting chest abnormalities, along with acid-fast staining and microscopic examination of the patient’s sputum. Extrapulmonary TB can be diagnosed using CT, MRI or ultrasound scans, endoscopy, laparoscopy, urine and blood tests, biopsies, and lumbar punctures.
The increasing prevalence of multi-drug resistant (MDR) tuberculosis across the globe is one of the key factors driving the growth of the market. MDR tuberculosis is caused by bacteria that are resistant to isoniazid and rifampicin, which are considered to be among the most potent antimicrobial drugs for TB. Furthermore, the availability of technologically advanced Point-of-Care (POC) diagnostic methods is also providing a boost to the market growth. Advanced diagnostic methods, such as Nucleic acid amplification tests (NAATs) and Interferon-Gamma Release Assay (IGRA), are more accurate, convenient, and provide prompt results in comparison to the traditionally used techniques. Additionally, significant improvements in the healthcare infrastructure, along with the growing awareness among the masses about various diagnostic procedures, are acting as another growth-inducing factor. Other factors, including the rising geriatric population and increasing healthcare expenditure and government initiatives and investments to promote research and development (R&D) activities, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global tuberculosis diagnostics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on disease stage, test type, and end-user.
Breakup by Disease Stage:
Breakup by Test Type:
Breakup by End-User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Laboratories, Alere Inc., Becton Dickinson and Company, BioMérieux, Cepheid Inc., Epistem Ltd., Roche Holding AG, Hain Lifescience GmbH, Hologic Inc., QIAGEN GmbH, Siemens, Thermo Fisher Scientific Inc., etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at